Product news

Share this article:
FDA has approved Takeda's Uloric (febuxostat), indicated for the chronic management of hyperuricemia in patients with gout. The once-daily product represents the first new treatment option in more than 40 years, according to a company release.
 
Device manufacturer C.R. Bard announced an FDA pre-market approval for its LifeStent FlexStar and FlexStar XL Vascular Stent Systems. The devices are approved for the treatment of occlusive disease in native superficial femoral arteries and proximal popliteal arteries, and are marketed by Bard's peripheral vascular division, in Tempe, AZ. 
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.